DK0806956T3 - Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling - Google Patents

Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling

Info

Publication number
DK0806956T3
DK0806956T3 DK96901696T DK96901696T DK0806956T3 DK 0806956 T3 DK0806956 T3 DK 0806956T3 DK 96901696 T DK96901696 T DK 96901696T DK 96901696 T DK96901696 T DK 96901696T DK 0806956 T3 DK0806956 T3 DK 0806956T3
Authority
DK
Denmark
Prior art keywords
cytostatic
bvdu
substituted nucleosides
resistance formation
cytostatic therapy
Prior art date
Application number
DK96901696T
Other languages
Danish (da)
English (en)
Inventor
Rudolf Fahrig
Angela Dr Steinkamp-Zucht
Original Assignee
Resprotect Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545892A external-priority patent/DE19545892A1/de
Application filed by Resprotect Gmbh filed Critical Resprotect Gmbh
Application granted granted Critical
Publication of DK0806956T3 publication Critical patent/DK0806956T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
DK96901696T 1995-02-01 1996-01-31 Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling DK0806956T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19503152 1995-02-01
DE19545892A DE19545892A1 (de) 1995-12-08 1995-12-08 Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU
PCT/DE1996/000169 WO1996023506A1 (de) 1995-02-01 1996-01-31 Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside

Publications (1)

Publication Number Publication Date
DK0806956T3 true DK0806956T3 (da) 2003-01-06

Family

ID=26012025

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96901696T DK0806956T3 (da) 1995-02-01 1996-01-31 Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling

Country Status (12)

Country Link
US (1) US6589941B1 (ko)
EP (1) EP0806956B1 (ko)
JP (1) JPH11502515A (ko)
KR (1) KR100330602B1 (ko)
AT (1) ATE222765T1 (ko)
BR (1) BR9607109A (ko)
DE (1) DE59609590D1 (ko)
DK (1) DK0806956T3 (ko)
ES (1) ES2180730T3 (ko)
NO (1) NO315258B1 (ko)
PT (1) PT806956E (ko)
WO (1) WO1996023506A1 (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840216D1 (de) * 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
DE19842578A1 (de) * 1998-09-17 2000-03-23 Max Delbrueck Centrum Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika
EP1200130A2 (en) 1999-07-22 2002-05-02 Newbiotics, Inc. Methods for treating therapy-resistant tumors
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
AU2451601A (en) * 1999-12-23 2001-07-03 Newbiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
DE10313035A1 (de) * 2003-03-24 2004-10-07 Resprotect Gmbh Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen
US20060269596A1 (en) * 2005-01-12 2006-11-30 Gary Liversidge Controlled release compositions comprising an acylanilide
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090068286A1 (en) * 2007-09-11 2009-03-12 Resprotect, Gmbh Method of treating cancer by administration of 5-substituted nucleosides
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069096A (en) * 1962-11-23 1967-05-17 Ile De Rech S Scient Et Ind So New organic derivatives of nucleotides and method for their manufacture
GB1473148A (ko) * 1974-09-16 1977-05-11
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
NL8700366A (nl) * 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5831064A (en) 1996-07-25 1998-11-03 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica

Also Published As

Publication number Publication date
KR19980701862A (ko) 1998-06-25
US6589941B1 (en) 2003-07-08
MX9705758A (es) 1997-10-31
ATE222765T1 (de) 2002-09-15
PT806956E (pt) 2003-01-31
EP0806956A1 (de) 1997-11-19
EP0806956B1 (de) 2002-08-28
NO315258B1 (no) 2003-08-11
WO1996023506A1 (de) 1996-08-08
BR9607109A (pt) 1997-11-04
DE59609590D1 (de) 2002-10-02
ES2180730T3 (es) 2003-02-16
JPH11502515A (ja) 1999-03-02
KR100330602B1 (ko) 2002-08-22
NO973529L (no) 1997-10-01
NO973529D0 (no) 1997-07-31

Similar Documents

Publication Publication Date Title
DK0806956T3 (da) Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling
MY127082A (en) Synergistic methods and compositions for treating cancer
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
WO2005009349A3 (en) Composition and method for treating neurological disorders
BR9904719A (pt) Composição para incrementar a permeabilidade de agentes tópicos à pele
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
WO2000066138A3 (en) Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
BR9814923A (pt) Método para tratamento de doença de alzheimer
WO2002053177A3 (en) Agents and methods for treating pain
BR0113961A (pt) Método de analgesia
GB0001449D0 (en) Compositions
DK0954334T3 (da) Anvendelse af makrofag migration inhibitorisk faktor antagonister til anti-cancer terapi
MX340217B (es) Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon.
DK1003546T3 (da) Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
CA2103458A1 (en) Method and composition to reduce myocardial reperfusion injury
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
DE69831000D1 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU6113701A (en) Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
CA2198580A1 (en) Combination therapy to treat osteoporosis
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy